Valuation: Sanofi

Market Cap 86.01B 98.02B 81.23B 74.03B 139B 9,394B 140B 972B 377B 4,799B 368B 360B 15,425B P/E 2026 *
11.4x
P/E 2027 * 9.96x
Enterprise Value 97.47B 111B 92.06B 83.89B 157B 10,646B 158B 1,102B 427B 5,439B 417B 408B 17,480B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.86x
Free-Float
88.34%
Yield 2026 *
5.93%
Yield 2027 * 6.26%
1 week-3.76%
Current month-6.77%
1 month-8.67%
3 months-2.72%
6 months-10.05%
Current year-13.53%
1 week 35.6
Extreme 35.6
37.2
1 month 35.6
Extreme 35.6
39.4
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer - 01/09/2026
Director TitleAgeSince
Director/Board Member 61 30/04/2019
Director/Board Member 56 28/04/2020
Director/Board Member 65 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.10%-3.76%-7.73% - 98.02B
+0.13%+2.65%+65.61%+114.28% 1,055B
+0.20%+0.46%+52.60%+69.24% 654B
-0.29%+0.14%+20.96%+70.93% 467B
-0.85%+0.98%+41.29%+44.38% 348B
+0.71%+4.08%+22.24%+29.51% 275B
+1.23%+0.42%+14.57%+12.13% 258B
+2.11%+7.51%+52.89%+55.37% 224B
+0.83%+0.55%+35.99%+101.70% 187B
0.00%-10.14%-29.94%-60.30% 171B
Average +0.36%+0.62%+26.85%+48.58% 404.26B
Weighted average by Cap. +0.02%+1.02%+40.24%+67.83%

Financials

2026 *2027 *
Net sales 47.65B 54.3B 45B 41.01B 76.77B 5,204B 77.32B 539B 209B 2,659B 204B 199B 8,545B 50.64B 57.71B 47.83B 43.59B 81.6B 5,532B 82.18B 572B 222B 2,826B 217B 212B 9,082B
Net income 7.48B 8.52B 7.06B 6.44B 12.05B 817B 12.14B 84.52B 32.74B 417B 32B 31.31B 1,341B 8.89B 10.13B 8.39B 7.65B 14.32B 971B 14.42B 100B 38.9B 496B 38.02B 37.2B 1,594B
Net Debt 11.46B 13.06B 10.83B 9.87B 18.47B 1,252B 18.6B 130B 50.18B 640B 49.05B 47.99B 2,056B 8.34B 9.5B 7.87B 7.17B 13.43B 910B 13.53B 94.21B 36.49B 465B 35.67B 34.9B 1,495B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Date Price Change
25/09/26 €35.80 -1.10%
24/09/26 €36.20 -1.09%
23/09/26 €36.60 -1.08%
22/09/26 €37.00 0.00%
21/09/26 €37.00 -0.54%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
71.79EUR
Average target price
94.06EUR
Spread / Average Target
+31.02%

Quarterly revenue - Rate of surprise